Abstract
Novel phosphoramidates of acyclovir have been prepared and evaluated in vitro against acyclovir-sensitive and -resistant herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus (VZV). Unlike the parent nucleoside these novel phosphate prodrugs retain antiviral potency versus the ACV-resistant virus strain, suggesting an efficient bypass of the viral thymidine kinase.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyclovir* / analogs & derivatives
-
Acyclovir* / chemical synthesis
-
Acyclovir* / chemistry
-
Acyclovir* / pharmacology
-
Acyclovir* / therapeutic use
-
Amides* / chemical synthesis
-
Amides* / chemistry
-
Amides* / pharmacology
-
Amides* / therapeutic use
-
Antiviral Agents* / chemical synthesis
-
Antiviral Agents* / chemistry
-
Antiviral Agents* / pharmacology
-
Antiviral Agents* / therapeutic use
-
Herpesvirus 1, Human / drug effects
-
Herpesvirus 2, Human / drug effects
-
Herpesvirus 3, Human
-
Humans
-
Molecular Structure
-
Phosphoric Acids* / chemical synthesis
-
Phosphoric Acids* / chemistry
-
Phosphoric Acids* / pharmacology
-
Phosphoric Acids* / therapeutic use
-
Prodrugs* / chemical synthesis
-
Prodrugs* / chemistry
-
Prodrugs* / pharmacology
-
Thymidine Kinase / metabolism*
Substances
-
Amides
-
Antiviral Agents
-
Phosphoric Acids
-
Prodrugs
-
phosphoramidic acid
-
Thymidine Kinase
-
Acyclovir